TIM-3 and PD-1 co-blockades enhanced the infiltration of CD8+TILs, and improved the anti-tumor immunity and proliferation of CD8+TILs (Fig. 3B, C and Supplementary Fig. 4). The gene discussed is HAVCR2; the disease is neoplasm.